A First-in-Human Study of SBP-9330 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects

This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.

Study Overview

• Status: Completed
• Conditions: Smoking Cessation
• Intervention / Treatment: Drug: SBP-9330; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 90
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Vijay Hingorani, MD, PhD; Phone Number: 858-864-8124; Email: clinicaltrials@caminopharma.com

Study Locations

• United States
  • Kansas
    • Overland Park, Kansas, United States, 66212
      • Altasciences Clinical Kansas, Inc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Provision of written informed consent prior to the initiation of any protocol-specific procedures
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Healthy male or female subject ≥ 18 and ≤ 55 years of age
4. Body mass index (BMI) ≥ 18.5 kg/m2 and ≤ 32.0 kg/m2
5. Body weight ≥ 50.0 kg at Screening
6. A female subject must meet at least one of the following criteria: a. Is of childbearing potential and agrees to use an acceptable contraceptive method. b. Is of non-childbearing potential, defined as surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (i.e., at least 1 year without menses prior to the first study drug administration without an alternative medical condition and confirmed with a serum follicle-stimulating hormone [FSH] > 40 IU/L at Screening)
7. Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from the first admission to the CRU until 90 days after the last study drug administration.
8. Part A and B only: Never- or nonsmoker (a nonsmoker is defined as someone who completely stopped using nicotine products for at least 2 years prior to the first study drug administration)
9. Have no clinically significant medical or mental health conditions captured in the medical history or evidence of clinically significant findings on the physical examination and/or ECG, as determined by an Investigator

10. No clinically significant abnormalities in blood pressure, heart rate, body temperature and respiratory rate and no evidence of orthostatic hypotension or postural tachycardia at Screening.

    Part C Only:

11. Are current tobacco cigarette smokers who smoke an average of 10 or more cigarettes per day in the 30 days prior to Screening
12. Expired breath CO level ≥10 parts per million (ppm) at Screening and prior to the first study drug administration
13. Positive test result for cotinine at Screening and prior to the first study drug administration
14. Are not motivated to try to quit smoking from Screening through 30 days from the first study drug administration

Exclusion Criteria:

1. Female who is lactating
2. Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration
3. Female who is planning to become pregnant during this study or within 90 days after the last study drug administration
4. Male with female partner who is pregnant, lactating, or planning to become pregnant during this study or within 90 days after the last study drug administration
5. Poor venous access as determined by an Investigator at Screening
6. History of significant hypersensitivity to SBP-9330 or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
7. Presence of any medical condition that, in the opinion of an Investigator, poses an unacceptable risk to the subjects
8. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug absorption
9. Evidence or history of clinically significant cardiovascular, pulmonary, hematologic, psychiatric (including mood and substance use disorders), neurological (including migraines, seizures, and epilepsy), endocrine, renal, hepatic, gastrointestinal, immunologic or dermatologic disease
10. History of malignancy within the past five years, except for successfully treated basal cell carcinoma of the skin
11. History of suicidal ideation or suicidal behavior as per the C-SSRS questionnaire administered at Screening
12. Evidence or history of significant psychiatric disease or any DSM-5 disorder as assessed by the Mini International Neuropsychiatric Interview (M.I.N.I.) administered at Screening
13. Routine or chronic use of more than three grams of acetaminophen daily
14. Strenuous activity, sunbathing, and contact sports within 48 hours prior to (first) admission to the CRU
15. Current alcohol consumption exceeding two standard drinks per day on average (1 standard drink=10 grams of alcohol) for male subjects and one standard drink per day on average for female subjects
16. History of alcohol or drug (other than caffeine) use disorder within 12 months prior to Screening
17. Any clinically significant illness in the 28 days prior to the first study drug administration
18. QTcF interval (QT interval corrected for heart rate according to Fridericia) > 450 ms for males and > 470 ms for females at Screening or on Day -1
19. Parts A and B only: Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration
20. Positive test results for HIV-1/HIV-2 antibodies, hepatitis B surface antigen or hepatitis C antibody
21. Consumption of any prescription drugs (with the exception of hormonal contraceptives or hormone replacement therapy) or over-the-counter medications and nutrients known to modulate cytochrome P450 (CYP450) enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange products) or St. John's Wort within 14 days prior to the first study drug administration
22. Consumption of other prescription and over-the-counter medication not specifically excluded by Exclusion Criterion 21 including health supplements and herbal remedies within 7 days prior to the first study drug administration (an exception is made for paracetamol [acetaminophen], which is allowed up to admission to the clinic).
23. Any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
24. Intake of an investigational product in the 30 days or 5 half-lives (whichever is longer) prior to Screening
25. Inclusion in a previous cohort of this clinical study
26. Employee of the contract research organization (CRO) or the Sponsor.
27. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening

28. Plasma donation within 7 days prior to Screening

    Part C Only:

29. History of generalized rash reaction to any drugs
30. Positive test result (except cotinine) for alcohol and/or drugs of abuse at Screening or prior to the first study drug administration
31. Use of smoking cessation aids (NRT, bupropion, or varenicline) within 30 days prior to the first study drug administration
32. Unable to abstain from smoking tobacco cigarettes for at least 1 hour before and 2 hours after study drug administration
33. Unable to abstain from using nicotine-containing products other than tobacco cigarettes (e.g., pipes, cigars, e-cigarettes or vapes, nicotine topical patches, nicotine gum, or nicotine lozenges) during the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

13

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part A1 - Single-Dose (Active; 150 mg ); In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.	Drug: SBP-9330; SBP-9330 oral capsules
Experimental: Part A3 - Single-Dose Food Effect (Active; 225 mg); In this two-period food-effect cohort, each healthy nonsmoker subject received the randomly assigned treatment (SBP-9330 or placebo) under fasting conditions (Period 1). After a 7- to 14-day washout period, subjects received the same single dose of SBP-9330 or placebo in a fed state (Period 2) 30 minutes after the start of an FDA High-Fat and High-Calorie Breakfast. A sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.	Drug: SBP-9330; SBP-9330 oral capsules
Experimental: Part A2 - Single-Dose (Active; 300 mg); In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.	Drug: SBP-9330; SBP-9330 oral capsules
Experimental: Part A4 - Single-Dose (Active; 450 mg); In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.	Drug: SBP-9330; SBP-9330 oral capsules
Experimental: Part A5 - Single-Dose (Active; 600 mg); In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.	Drug: SBP-9330; SBP-9330 oral capsules
Placebo Comparator: Part A - Single-Dose (Placebo; pooled); In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.	Drug: Placebo; Placebo oral capsules
Experimental: Part B1 - Multiple-Dose Active (150 mg); In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.	Drug: SBP-9330; SBP-9330 oral capsules
Experimental: Part B2 - Multiple-Dose Active (225 mg); In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.	Drug: SBP-9330; SBP-9330 oral capsules
Experimental: Part B3 - Multiple-Dose Active (300 mg); In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.	Drug: SBP-9330; SBP-9330 oral capsules
Placebo Comparator: Part B - Multiple-Dose Placebo (pooled); In Part B, cohorts of healthy nonsmokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.	Drug: Placebo; Placebo oral capsules
Experimental: Part C1 - Smoker Phase (Active; 150 mg); In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.	Drug: SBP-9330; SBP-9330 oral capsules
Experimental: Part C2 - Smoker Phase (Active; 225 mg); In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.	Drug: SBP-9330; SBP-9330 oral capsules
Placebo Comparator: Part C - Smoker Phase (Placebo; pooled); In Part C, cohorts of healthy smokers were randomized to receive once daily doses of active SBP-9330 or matching placebo for 14 consecutive days in increasing dose cohorts.	Drug: Placebo; Placebo oral capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Treatment-Emergent Adverse Events [Safety and Tolerability]	Number of drug-related adverse events as determined by clinically significant changes in vital signs, physical examination findings, ECG parameters, C-SSRS questionnaire results, and clinical laboratory results	Part A: 8 days Part B: 21 days Part C: 21 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics of SBP-9330: Cmax	Maximum observed concentration (Cmax)	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: Tmax	Time to reach maximum observed concentration (Tmax)	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: AUC 0-24	Area under the concentration time curve from time 0 (dose administration) to 24 hours	PK samples were obtained at selected timepoints from pre-dose until 24 hours post-dose
Pharmacokinetics of SBP-9330: AUC 0-T	Area under the concentration time curve from time 0 (dose administration) to the time of last quantifiable concentration	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: AUC 0-∞	Area under the concentration time curve extrapolated to infinity	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: T½	Terminal elimination half-life	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: CL/F	Apparent total clearance	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: Vz/F	Apparent volume of distribution	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: C Trough	Observed concentration at the end of the dosing interval	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: Cτ	Concentration at the end of the dosing interval.	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: AUCτ	Area under the concentration time curve over the dosing interval at steady state, calculated from 0 to 24 hours (dosing interval)	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: T½, Eff	Effective half-life	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: CL/Fss	Apparent total clearance at steady state	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: Vz/Fss	Apparent volume of distribution at steady state	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: RAC(Cmax)	Accumulation ratio evaluated by comparing Day 14 Cmax to Day 1 Cmax	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose
Pharmacokinetics of SBP-9330: RAC(AUC)	Accumulation ratio evaluated by comparing Day 14 AUCτ to Day 1 AUC0-24	PK samples were obtained at selected timepoints from pre-dose until 48 hours post-dose

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Minnesota Nicotine Withdrawal Scale (MNWS)	A self-report measure used to monitor symptoms of tobacco withdrawal.	Screening through Day 14
Expired Carbon Monoxide (ECO) Level	Expired breath CO was measured with a Bedfont Smokerlyzer™	Daily from Screening through Day 14
Plasma Cotinine Level	Blood samples were collected to measure plasma cotinine levels	Predose, Day 7 and Day 14
Number of Cigarettes Smoked	A daily smoking log was kept to document the number of cigarettes smoked	Daily from Screening through Day 14
Questionnaire on Smoking Urges - Brief Version (QSU-Brief)	A self-report questionnaire used to measure cravings to smoke.	Screening through Day 15

Collaborators and Investigators

• Sponsor: Camino Pharma, LLC
• Collaborators: National Institute on Drug Abuse (NIDA); University of California, San Diego; Sanford Burnham Prebys Medical Discovery Institute

Study record dates

Study Major Dates

• Study Start (Actual): July 20, 2021
• Primary Completion (Actual): March 6, 2023
• Study Completion (Actual): March 6, 2023

Study Registration Dates

• First Submitted: June 15, 2021
• First Submitted That Met QC Criteria: June 24, 2021
• First Posted (Actual): July 2, 2021

Study Record Updates

• Last Update Posted (Actual): April 16, 2024
• Last Update Submitted That Met QC Criteria: March 19, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: SBP-9330-101; U01DA051077 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No